FK 143

Drug Profile

FK 143

Latest Information Update: 17 Jul 2002

Price : $50

At a glance

  • Originator Fujisawa
  • Class Antiandrogens
  • Mechanism of Action Cholestenone 5-alpha reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Hepatocellular carcinoma
  • Discontinued Benign prostatic hyperplasia

Most Recent Events

  • 25 Oct 2000 A preclinical study has been added to the Cancer pharmacodynamics section
  • 25 Oct 2000 Preclinical development for Hepatocellular carcinoma in Japan (Unknown route)
  • 08 Jul 1998 A clinical study has been added to the pharmacokinetic and Men's Health pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top